Pfizer’s new tablet to treat coronavirus begins human trial: 5 things to know
The new protease inhibitor is the second such medicine Pfizer has brought into human trials to treat Covid-19.
Pfizer Inc on Tuesday announced it is progressing to multiple ascending doses after completing the dosing of single ascending doses in a Phase 1 study in healthy adults to evaluate the safety and tolerability of a new pill to treat the coronavirus that could be used at the first sign of illness.
This Phase 1 trial is being conducted in the United States. The oral antiviral clinical candidate PF-07321332, a SARS-CoV2-3CL protease inhibitor, has demonstrated potent in vitro anti-viral activity against SARS-CoV-2, as well as activity against other coronaviruses.
“Tackling the COVID-19 pandemic requires both prevention via vaccine and targeted treatment for those who contract the virus. Given the way that SARS-CoV-2 is mutating and the continued global impact of COVID-19, it appears likely that it will be critical to have access to therapeutic options both now and beyond the pandemic,”said Mikael Dolsten, Pfizer’s Chief Scientific Officer, in a statement.
The new protease inhibitor is the second such medicine Pfizer has brought into human trials to treat Covid-19. Pfizer is testing another given intravenously to hospitalized virus patients.
"The Phase 1 trial is a randomized, double-blind, sponsor-open, placebo-controlled, single- and multiple-dose escalation study in healthy adults evaluating the safety, tolerability and pharmacokinetics of PF-07321332," the company said in a statement,
Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
Business NewsScienceNewsPfizer’s new tablet to treat coronavirus begins human trial: 5 things to know
First Published:24 Mar 2021, 09:27 AM IST
- Top Gainers
- Top Losers
- 52 Week High